Different dose regimens of a SARS-CoV-2 recombinant spike pr

In a phase 2 randomized placebo-controlled trial, Neil Formica and coauthors investigate the immunogenicity and safety of different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine in younger and older adults in USA and Australia.

Related Keywords

United Kingdom , United States , Australia , New Zealand , Texas , South Africa , Maryland , Melbourne , Victoria , Baylor College Of Medicine , Mark Adams , Terry Klein , Fiona Napier , Paul Griffin , Jason Lickliter , Mark Arya , Cheryl Keech , Amber Leah , Paul Nugent , Susan Thackwray , Novavax Gaithersburg , Ira Berger , Mark Turner , Joshua Kim , Astrazeneca Oxford , Charlotte Lemech , Paul Bradley , Mary Beth Manning , Maheshin Ramasamy , University Of Oxford , International Conference On Harmonisation , Department Of Defense , Study Group , Drug Administration , Melinda Gates Foundation , Coalition Of Epidemic Preparedness Innovations , Coalition For Epidemic Preparedness Innovations , Phase Five Communications , Alfred Hospital Human Research Ethics Committee Melbourne , Baylor College Of Medicine Houston , Pearson , Novavax Inc , Creative Commons Attribution License , Supporting Information , Epidemic Preparedness Innovations , Operation Warp Speed , Epidemic Preparedness , Alfred Hospital Human Research Ethics Committee , Advarra Central Institutional Review Board , International Conference , Good Clinical Practice , Medical Dictionary , Regulatory Activities , Baylor College , Analysis Sets , Per Protocol Analysis Set , Safety Analysis Set , Eugene Athan , Richard Glover , Scott Kitchener , Fiona Napier Flood , Vaccination And Immunization , Sars Cov 2 , Antibodies , Vaccines , Enzyme Linked Immunoassays , Age Groups , Antibody Response , Antigens ,